Skip to content
A840 PRESURVEY - Know-It-When-You-See-It: Diagnosis and Initial Treatment of Oral Pemphigus Vulgaris
PLEASE COMPLETE THIS PRESURVEY BEFORE THE START OF THE PRESENTATION.
Know-It-When-You-See-It: Diagnosis and Initial Treatment of Oral Pemphigus Vulgaris
PRETEST
1.
Which of the following symptoms is consistent with oral pemphigus vulgaris?
A. Oral white patches
B. Oral flaccid blisters and ulcers
C. Small white keratinized oral plaques
D. Self-limited scarring oral blisters
2.
Which of the following tests can be used to confirm a diagnosis of pemphigus vulgaris?
A. ELISA for anti-keratin antibodies
B. Nikolsky’s sign
C. Epidermal IgG deposits by direct immunofluorescence
D. Physical presentation
3.
A 36-year-old man presents to you with oral lesions suggestive of pemphigus vulgaris. Which of the following would confirm the diagnosis of PV?
a. Biopsy with both H and E staining showing acantholysis and direct immunofluorescence showing intercellular IgG
b. Biopsy with H and E staining showing epidermal denudation and ELISPOT showing desmoglein-specific B cells
c. Positive ELISA for anti-desmoglein 1 and 3 antibodies
d. Positive Indirect immunofluorescence for circulating IgG antibodies
4.
A 42-year-old woman presents with diagnosed pemphigus vulgaris. Based on current guidelines, what treatment approach would you recommend?
A. Topical corticosteroids
B. Rituximab plus prednisone
C. Cyclophosphamide plus prednisone
D. Prednisone monotherapy
5.
Prior to
participating in this activity, how confident are you in your
ability to
:
1-Not at all confident
2-Somewhat confident
3-Confident
4-Very confident
Diagnose oral PV based on presenting symptoms and appropriate testing
1-Not at all confident
2-Somewhat confident
3-Confident
4-Very confident
Outline initial and long-term treatment plans for patients with oral PV
1-Not at all confident
2-Somewhat confident
3-Confident
4-Very confident
*
6.
Please indicate the meeting you will be attending:
(Required.)
Greater New York Dental: November 27, 2020
American Dental Association (ADA): April 29, 2021
*
7.
Please complete the following
(Required.)
Full Name
Email
*
8.
Paradigm Medical Communications, LLC may email information about this and other continuing education activities to the email address indicated above
(Required.)
Yes
No